A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia (SOLARIS)
- Study Title
- A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients with Schizophrenia (SOLARIS)
- Teva Identifier
- TV44749-CNS-30096
- ClinicalTrials.gov Identifier
- NCT05693935
- Study Status
- Completed
- Trial Condition(s)
- Schizophrenia
- Interventions
- Drug: TV-44749 | Drug: Placebo
- EudraCT Number
- 2022-001865-11
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult
- Age Range
- 18 Years to 64 Years
- Trial Duration
- January 24, 2023 - January 27, 2025
- Phase
- Phase 3